Insider Transactions in Q2 2021 at Pulmonx Corp (LUNG)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 25
2021
|
Daniel P Florin |
BUY
Open market or private purchase
|
Direct |
2,222
+30.63%
|
$97,768
$44.12 P/Share
|
|
Jun 17
2021
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Indirect |
1,000
-3.76%
|
$42,000
$42.68 P/Share
|
|
Jun 17
2021
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Direct |
25,000
-1.0%
|
$1,075,000
$43.15 P/Share
|
|
Jun 17
2021
|
Glendon E. French Iii |
BUY
Exercise of conversion of derivative security
|
Direct |
4,375
+0.35%
|
$8,750
$2.2 P/Share
|
|
Jun 01
2021
|
Thomas William Burns |
BUY
Grant, award, or other acquisition
|
Direct |
2,810
+50.0%
|
-
|
|
Jun 01
2021
|
Richard Ferrari |
BUY
Grant, award, or other acquisition
|
Direct |
2,810
+12.89%
|
-
|
|
Jun 01
2021
|
Daniel P Florin |
BUY
Grant, award, or other acquisition
|
Direct |
2,810
+50.0%
|
-
|
|
Jun 01
2021
|
Glendon E. French Iii |
BUY
Grant, award, or other acquisition
|
Direct |
45,600
+3.53%
|
-
|
|
Jun 01
2021
|
David Aaron Lehman GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
17,600
+50.0%
|
-
|
|
Jun 01
2021
|
Dana G Mead Jr. |
BUY
Grant, award, or other acquisition
|
Direct |
2,810
+8.8%
|
-
|
|
Jun 01
2021
|
Georgia Melenikiotou |
BUY
Grant, award, or other acquisition
|
Direct |
2,810
+50.0%
|
-
|
|
Jun 01
2021
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,600
+8.87%
|
-
|
|
Jun 01
2021
|
Derrick Sung Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,600
+6.88%
|
-
|
|
May 24
2021
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,797
-0.72%
|
$196,677
$41.34 P/Share
|
|
May 20
2021
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Indirect |
1,000
-3.63%
|
$40,000
$40.75 P/Share
|
|
May 20
2021
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Direct |
25,000
-1.02%
|
$1,025,000
$41.6 P/Share
|
|
May 18
2021
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
49,428
+22.93%
|
$49,428
$1.4 P/Share
|
|
May 10
2021
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,797
-0.99%
|
$196,677
$41.68 P/Share
|
|
Apr 19
2021
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,797
-3.8%
|
$206,271
$43.24 P/Share
|
|
Apr 15
2021
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Indirect |
1,000
-3.5%
|
$43,000
$43.7 P/Share
|
|
Apr 15
2021
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Direct |
25,000
-1.0%
|
$1,075,000
$43.92 P/Share
|
|
Apr 06
2021
|
Boston Scientific Corp > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
650,000
-14.01%
|
$27,950,000
$43.6 P/Share
|
|
Apr 06
2021
|
Derrick Sung Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-0.75%
|
$235,000
$47.54 P/Share
|
|
Apr 05
2021
|
Derrick Sung Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.09%
|
$240,000
$48.06 P/Share
|
|
Apr 05
2021
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,797
-2.11%
|
$230,256
$48.03 P/Share
|